Boehringer Ingelheim starts work of $217m expansion project in California
July 26, 20017 – Boehringer Ingelheim, a privately-held pharmaceutical firm, has broken ground on a $217m project to expand human biologics manufacturing facility in Fremont, California.
Recently, the site secured $25.5m in two separate tax credits from California, making them the largest award to a pharmaceutical company.
The expansion will create approximately 300 new high-wage and highly-skilled positions to the city of Fremont.
Boehringer Ingelheim Fremont president and CEO Jens Vogel said: “The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California.
“We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”
California state Treasurer John Chiang said: “The State Treasurer’s Office is excited to play a role in helping Boehringer Ingelheim expand and create nearly 300 permanent, high-paying jobs right here in California.
“The incentives my office provides ensure that California will retain and create jobs, bolster the economy and clean the environment, today and into the future.”